424 related articles for article (PubMed ID: 16953186)
21. Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor.
Meschler JP; Kraichely DM; Wilken GH; Howlett AC
Biochem Pharmacol; 2000 Nov; 60(9):1315-23. PubMed ID: 11008125
[TBL] [Abstract][Full Text] [Related]
22. Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers.
Bingham B; Jones PG; Uveges AJ; Kotnis S; Lu P; Smith VA; Sun SC; Resnick L; Chlenov M; He Y; Strassle BW; Cummons TA; Piesla MJ; Harrison JE; Whiteside GT; Kennedy JD
Br J Pharmacol; 2007 Aug; 151(7):1061-70. PubMed ID: 17549048
[TBL] [Abstract][Full Text] [Related]
23. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
Haller VL; Cichewicz DL; Welch SP
Eur J Pharmacol; 2006 Sep; 546(1-3):60-8. PubMed ID: 16919265
[TBL] [Abstract][Full Text] [Related]
24. Sch35966 is a potent, selective agonist at the peripheral cannabinoid receptor (CB2) in rodents and primates.
Gonsiorek W; Lunn CA; Fan X; Deno G; Kozlowski J; Hipkin RW
Br J Pharmacol; 2007 Aug; 151(8):1262-71. PubMed ID: 17603556
[TBL] [Abstract][Full Text] [Related]
25. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain.
Sain NM; Liang A; Kane SA; Urban MO
Neuropharmacology; 2009 Sep; 57(3):235-41. PubMed ID: 19538975
[TBL] [Abstract][Full Text] [Related]
26. Significance of cannabinoid CB1 receptors in improgan antinociception.
Gehani NC; Nalwalk JW; Razdan RK; Martin BR; Sun X; Wentland M; Abood ME; Hough LB
J Pain; 2007 Nov; 8(11):850-60. PubMed ID: 17644043
[TBL] [Abstract][Full Text] [Related]
27. Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development.
Ford BM; Franks LN; Radominska-Pandya A; Prather PL
PLoS One; 2016; 11(12):e0167240. PubMed ID: 27936172
[TBL] [Abstract][Full Text] [Related]
28. Novel selective antagonist of the cannabinoid CB1 receptor, MJ15, with prominent anti-obesity effect in rodent models.
Chen W; Tang H; Liu H; Long L; Gong Z; Zheng J; Chi M; Xie Y; Zheng Z; Li S; Wang L
Eur J Pharmacol; 2010 Jul; 637(1-3):178-85. PubMed ID: 20380831
[TBL] [Abstract][Full Text] [Related]
29. Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat.
Dyson A; Peacock M; Chen A; Courade JP; Yaqoob M; Groarke A; Brain C; Loong Y; Fox A
Pain; 2005 Jul; 116(1-2):129-37. PubMed ID: 15936883
[TBL] [Abstract][Full Text] [Related]
30. Suppression of food intake and food-reinforced behavior produced by the novel CB1 receptor antagonist/inverse agonist AM 1387.
McLaughlin PJ; Qian L; Wood JT; Wisniecki A; Winston KM; Swezey LA; Ishiwari K; Betz AJ; Pandarinathan L; Xu W; Makriyannis A; Salamone JD
Pharmacol Biochem Behav; 2006 Mar; 83(3):396-402. PubMed ID: 16616951
[TBL] [Abstract][Full Text] [Related]
31. Discovery of 7-oxopyrazolo[1,5-a]pyrimidine-6-carboxamides as potent and selective CB(2) cannabinoid receptor inverse agonists.
Aghazadeh Tabrizi M; Baraldi PG; Saponaro G; Moorman AR; Romagnoli R; Preti D; Baraldi S; Ruggiero E; Tintori C; Tuccinardi T; Vincenzi F; Borea PA; Varani K
J Med Chem; 2013 Jun; 56(11):4482-96. PubMed ID: 23697626
[TBL] [Abstract][Full Text] [Related]
32. Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.
Thomas A; Stevenson LA; Wease KN; Price MR; Baillie G; Ross RA; Pertwee RG
Br J Pharmacol; 2005 Dec; 146(7):917-26. PubMed ID: 16205722
[TBL] [Abstract][Full Text] [Related]
33. Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging.
Yao BB; Hsieh G; Daza AV; Fan Y; Grayson GK; Garrison TR; El Kouhen O; Hooker BA; Pai M; Wensink EJ; Salyers AK; Chandran P; Zhu CZ; Zhong C; Ryther K; Gallagher ME; Chin CL; Tovcimak AE; Hradil VP; Fox GB; Dart MJ; Honore P; Meyer MD
J Pharmacol Exp Ther; 2009 Jan; 328(1):141-51. PubMed ID: 18931146
[TBL] [Abstract][Full Text] [Related]
34. Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1.
Mo FM; Offertáler L; Kunos G
Eur J Pharmacol; 2004 Apr; 489(1-2):21-7. PubMed ID: 15063151
[TBL] [Abstract][Full Text] [Related]
35. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
Fong TM; Guan XM; Marsh DJ; Shen CP; Stribling DS; Rosko KM; Lao J; Yu H; Feng Y; Xiao JC; Van der Ploeg LH; Goulet MT; Hagmann WK; Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Francis B; Strack AM; MacIntyre DE; Shearman LP
J Pharmacol Exp Ther; 2007 Jun; 321(3):1013-22. PubMed ID: 17327489
[TBL] [Abstract][Full Text] [Related]
36. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes.
Griffin G; Atkinson PJ; Showalter VM; Martin BR; Abood ME
J Pharmacol Exp Ther; 1998 May; 285(2):553-60. PubMed ID: 9580597
[TBL] [Abstract][Full Text] [Related]
38. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide.
Gonsiorek W; Lunn C; Fan X; Narula S; Lundell D; Hipkin RW
Mol Pharmacol; 2000 May; 57(5):1045-50. PubMed ID: 10779390
[TBL] [Abstract][Full Text] [Related]
39. Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist.
Cascio MG; Gauson LA; Stevenson LA; Ross RA; Pertwee RG
Br J Pharmacol; 2010 Jan; 159(1):129-41. PubMed ID: 20002104
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Felder CC; Joyce KE; Briley EM; Mansouri J; Mackie K; Blond O; Lai Y; Ma AL; Mitchell RL
Mol Pharmacol; 1995 Sep; 48(3):443-50. PubMed ID: 7565624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
